A Phase 2 interventional study of Apremilast and Apremilast in Dermatitis, Atopic Dermatitis, sponsored by Amgen. Completed at 31 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-05-07.
Sponsored by Amgen · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Dermatitis, Atopic by Amgen — none open to participants now, none under way, none of them phase 3. Dermatitis, Atopic · Amgen.
Among the 15 studies in Dermatitis, Atopic by Amgen, this one is the 10th largest by enrollment, is the only one that started in 2014, is one of 2 in phase 2, and was the 2nd registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →None of the 15 studies in Dermatitis, Atopic by Amgen is open now. The open studies under Dermatitis, Atopic, anywhere →
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 191 is above the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 231 across the 15 interventional studies. Of the 15 that completed or were terminated, 10 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 15 studies in Dermatitis, Atopic by Amgen, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A study to evaluate the efficacy and safety of apremilast (CC-10004) in subjects with moderate to severe atopic dermatitis
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Apremilast 40 mg administered orally twice daily (BID) for 12 weeks (following dose titration) during the placebo controlled phase followed by 40 mg Apremilast tablets orally administered BID for an additional 12 weeks in the active treatment phase
Drug: Apremilast
Apremilast 30 mg administered orally BID for 12 weeks (following dose titration) during the placebo controlled phase followed by 30 mg Apremilast tablets orally administered BID for an additional 12 weeks in the active treatment phase
Drug: Apremilast
Placebo administered orally BID for 12 weeks, during the placebo controlled phase followed by 40 mg Apremilast tablets orally BID for an additional 12 weeks in the active treatment phase
Drug: Apremilast · Drug: Placebo
Placebo administered orally BID for 12 weeks, during the placebo controlled phase followed by 30 mg Apremilast tablets orally BID for an additional 12 weeks in the active treatment phase
Drug: Apremilast · Drug: Placebo
Oral Placebo tablets administered twice daily (BID) for 12 weeks during the placebo-controlled phase.
Drug: Placebo
Orally twice a day (BID)
Also known as: CC-10004, Otezla
Orally twice a day (BID)
Also known as: CC-10004, Otezla
Orally twice a day (BID)
Orally twice a day (BID)
Percentage Change From Baseline in the Eczema Area and Severity Index (EASI) Score at Week 12.
EASI is a validated composite scoring system integrating the proportion of the body region (area) involved and the intensity of key signs of atopic dermatitis (AD). A representative lesion is selected for each of the four body regions for assessing the intensity of each of the four signs (erythema, induration /papulation, excoriation, and lichenification). Symptoms (eg, pruritus) and secondary signs (eg, xerosis, scaling) are excluded from the assessment. The total EASI score ranges from 0 to 72. A higher score indicated worse disease status, and a negative change from baseline indicated improvement.
Time frame: Baseline to Week 12
Percentage of Participants Who Achieved a Score of 0 (Cleared) or 1 (Almost Cleared) and at Least a 2-point Reduction From Baseline in a Static Physician's Global Assessment of Acute Signs (sPGA-A) at Week 12.
The sPGA-A is intended to assess the global severities (ie, a "visual average" integrating all areas of AD) of key acute clinical signs of AD, including erythema, induration/papulation, oozing/crusting (lichenification excluded) based on a 5-point scale of cleared (0), almost cleared (1), mild (2), moderate (3) and severe (4).
Time frame: Baseline to Week 12
Percentage of Participants Who Achieved at Least a 50% Reduction From Baseline in the EASI Score (EASI 50) at Week 12
The EASI 50 reduction (defined as ≥ 50% reduction from baseline in EASI score) was selected to serve as the key responder endpoint. A ≥ 50% improvement is clinically meaningful for this population.
Time frame: Baseline to Week 12
The Percentage Change From Baseline in the Average Weekly Pruritus Numerical Rating Scale (NRS) Score at Week 4
The participant completed a daily diary recording the average intensity of pruritus they experienced during the preceding 24 hrs. The intensity of pruritus was assessed using a validated 11-point NRS, ranging from 0 ("no pruritus") to 10 ("the worst pruritus imaginable"). It should be noted that this NRS is distinct from the pruritus, Visual Analogue Scale (VAS) in the Modified SCORAD Index with respect to recall period (three days for the VAS). The weekly NRS score was calculated as the average of the NRS scores over 7 days within the specified week. A higher score indicated worse disease status, and a negative change from baseline indicated improvement.
Time frame: Baseline to Week 4
Number of Participants With Treatment Emergent Adverse Events (TEAEs) During the Placebo Controlled Period
A TEAE is an adverse event with a start date on or after the date of the first dose of IP and no later than 28 days after the last dose of IP for participants who discontinued early. An adverse event (AE) is any noxious, unintended, or untoward medical occurrence that may appear or worsen during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values, regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a pre existing condition) should be considered an AE. A serious AE is any which results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect; constitutes an important medical event.
Time frame: Baseline to Week 12
Number of Participants With TEAEs During the Apremilast Exposure Period
A TEAE is an adverse event with a start date on or after the date of the first dose of investigational product (IP) and no later than 28 days after the last dose of IP. An adverse event (AE) is any noxious, unintended, or untoward medical occurrence that may appear or worsen during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values, regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a pre existing condition) should be considered an AE. A serious AE is any which results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect; constitutes an important medical event.
Time frame: Baseline to Week 24; median duration of apremilast 30 mg was 23.3 weeks and 22.4 weeks for apremilast 40 mg
| Milestone | Placebo | Apremilast 30 mg | Apremilast 40 mg | Placebo/Apremilast 30 mg | Placebo/Apremilast 40 mg |
|---|---|---|---|---|---|
| Started | 64 | 58 | 63 | 0 | 0 |
| Safety population | 64 | 58 | 63 | 0 | 0 |
| Completed | 50 | 46 | 50 | 0 | 0 |
| Not completed | 14 | 12 | 13 | 0 | 0 |
| Withdrew: Adverse event | 1 | 2 | 6 | 0 | 0 |
| Withdrew: Lack of efficacy | 8 | 7 | 4 | 0 | 0 |
| Withdrew: Withdrawal by subject | 4 | 2 | 2 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 1 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 1 | 0 | 0 | 0 |
| Milestone | Placebo | Apremilast 30 mg | Apremilast 40 mg | Placebo/Apremilast 30 mg | Placebo/Apremilast 40 mg |
|---|---|---|---|---|---|
| Started | 0 | 46 | 49 | 24 | 23 |
| Completed | 0 | 42 | 44 | 22 | 21 |
| Not completed | 0 | 4 | 5 | 2 | 2 |
| Withdrew: Adverse event | 0 | 1 | 2 | 0 | 1 |
| Withdrew: Lack of efficacy | 0 | 3 | 1 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Other-unspecified | 0 | 0 | 1 | 1 | 0 |
| Milestone | Placebo | Apremilast 30 mg | Apremilast 40 mg | Placebo/Apremilast 30 mg | Placebo/Apremilast 40 mg |
|---|---|---|---|---|---|
| Started | 0 | 46 | 48 | 24 | 23 |
| Completed | 0 | 46 | 45 | 23 | 22 |
| Not completed | 0 | 0 | 3 | 1 | 1 |
EASI is a validated composite scoring system integrating the proportion of the body region (area) involved and the intensity of key signs of atopic dermatitis (AD). A representative lesion is selected for each of the four body regions for assessing the intensity of each of the four signs (erythema, induration /papulation, excoriation, and lichenification). Symptoms (eg, pruritus) and secondary signs (eg, xerosis, scaling) are excluded from the assessment. The total EASI score ranges from 0 to 72. A higher score indicated worse disease status, and a negative change from baseline indicated improvement.
| percent change | Placebo | Apremilast 30 mg | Apremilast 40 mg |
|---|---|---|---|
| Percentage Change From Baseline in the Eczema Area and Severity Index (EASI) Score at Week 12. | -10.98 ± 6.873 | -25.99 ± 7.106 | -31.57 ± 6.820 |
The sPGA-A is intended to assess the global severities (ie, a "visual average" integrating all areas of AD) of key acute clinical signs of AD, including erythema, induration/papulation, oozing/crusting (lichenification excluded) based on a 5-point scale of cleared (0), almost cleared (1), mild (2), moderate (3) and severe (4).
| percentage of participants | Placebo | Apremilast 30 mg | Apremilast 40 mg |
|---|---|---|---|
| Percentage of Participants Who Achieved a Score of 0 (Cleared) or 1 (Almost Cleared) and at Least a 2-point Reduction From Baseline in a Static Physician's Global Assessment of Acute Signs (sPGA-A) at Week 12. | 6.3 | 3.4 | 14.3 |
The EASI 50 reduction (defined as ≥ 50% reduction from baseline in EASI score) was selected to serve as the key responder endpoint. A ≥ 50% improvement is clinically meaningful for this population.
| percentage of participants | Placebo | Apremilast 30 mg | Apremilast 40 mg |
|---|---|---|---|
| Percentage of Participants Who Achieved at Least a 50% Reduction From Baseline in the EASI Score (EASI 50) at Week 12 | 32.8 | 31.0 | 42.9 |
The participant completed a daily diary recording the average intensity of pruritus they experienced during the preceding 24 hrs. The intensity of pruritus was assessed using a validated 11-point NRS, ranging from 0 ("no pruritus") to 10 ("the worst pruritus imaginable"). It should be noted that this NRS is distinct from the pruritus, Visual Analogue Scale (VAS) in the Modified SCORAD Index with respect to recall period (three days for the VAS). The weekly NRS score was calculated as the average of the NRS scores over 7 days within the specified week. A higher score indicated worse disease status, and a negative change from baseline indicated improvement.
| percent change | Placebo | Apremilast 30 mg | Apremilast 40 mg |
|---|---|---|---|
| The Percentage Change From Baseline in the Average Weekly Pruritus Numerical Rating Scale (NRS) Score at Week 4 | -4.83 ± 5.657 | -10.00 ± 5.911 | -9.00 ± 5.850 |
A TEAE is an adverse event with a start date on or after the date of the first dose of IP and no later than 28 days after the last dose of IP for participants who discontinued early. An adverse event (AE) is any noxious, unintended, or untoward medical occurrence that may appear or worsen during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values, regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a pre existing condition) should be considered an AE. A serious AE is any which results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect; constitutes an important medical event.
| participants | Placebo | Apremilast 30 mg | Apremilast 40 mg |
|---|---|---|---|
| TEAE | 30 | 36 | 44 |
| Drug-related TEAE | 8 | 26 | 27 |
| Severe TEAE | 0 | 0 | 1 |
| Serious TEAE (SAE) | 0 | 1 | 2 |
| Drug-related SAE | 0 | 0 | 1 |
| TEAE Leading to Drug Interruption | 3 | 0 | 4 |
| TEAE Leading to Drug Withdrawal | 1 | 2 | 6 |
| Death | 0 | 0 | 0 |
A TEAE is an adverse event with a start date on or after the date of the first dose of investigational product (IP) and no later than 28 days after the last dose of IP. An adverse event (AE) is any noxious, unintended, or untoward medical occurrence that may appear or worsen during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values, regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a pre existing condition) should be considered an AE. A serious AE is any which results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect; constitutes an important medical event.
| participants | Apremilast 30 mg | Apremilast 40 mg |
|---|---|---|
| TEAE | 49 | 61 |
| Drug-related TEAE | 29 | 38 |
| Severe TEAE | 1 | 1 |
| Serious TEAE (SAE) | 2 | 3 |
| Drug-related SAE | 0 | 2 |
| TEAE Leading to Drug Interruption | 0 | 8 |
| TEAE Leading to Drug Withdrawal | 3 | 9 |
| Death | 0 | 0 |
Collected over Adverse Events are reported for the 12-week placebo-controlled phase and up to 24 weeks for all participants who received apremilast at any time during the study. All TEAEs were recorded by the investigator from the time the participant received the first dose of study drug to no later than 28 days after the last dose of study drug.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo (Weeks 0-12) | — | 0/64 (0%) | 14/64 (21.9%) |
| Apremilast 30 mg (Weeks 0-12) | — | 1/58 (1.7%) | 22/58 (37.9%) |
| Apremilast 40 mg (Weeks 0-12) | — | 2/63 (3.2%) | 30/63 (47.6%) |
| Apremilast 30 mg (Apremilast Exposure Period) 0-24 | — | 2/82 (2.4%) | 30/82 (36.6%) |
| Apremilast 40 mg (Apremilast Exposure Period) 0-24 | — | 3/86 (3.5%) | 45/86 (52.3%) |
| Event | Placebo (Weeks 0-12) | Apremilast 30 mg (Weeks 0-12) | Apremilast 40 mg (Weeks 0-12) | Apremilast 30 mg (Apremilast Exposure Period) 0-24 | Apremilast 40 mg (Apremilast Exposure Period) 0-24 |
|---|---|---|---|---|---|
| CellulitisInfections and infestations | 0/64 | 0/58 | 1/63 | 0/82 | 2/86 |
| Squamous Cell CarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/64 | 1/58 | 0/63 | 1/82 | 0/86 |
| Suicidal ideationPsychiatric disorders | 0/64 | 0/58 | 1/63 | 0/82 | 1/86 |
| GlomerulonephritisRenal and urinary disorders | 0/64 | 0/58 | 1/63 | 0/82 | 1/86 |
| PneumoniaInfections and infestations | 0/64 | 0/58 | 0/63 | 1/82 | 0/86 |
| Event | Placebo (Weeks 0-12) | Apremilast 30 mg (Weeks 0-12) | Apremilast 40 mg (Weeks 0-12) | Apremilast 30 mg (Apremilast Exposure Period) 0-24 | Apremilast 40 mg (Apremilast Exposure Period) 0-24 |
|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 1/64 | 10/58 | 15/63 | 11/82 | 21/86 |
| NasopharyngitisInfections and infestations | 1/64 | 6/58 | 6/63 | 8/82 | 14/86 |
| NauseaGastrointestinal disorders | 1/64 | 9/58 | 7/63 | 10/82 | 14/86 |
| HeadacheNervous system disorders | 5/64 | 4/58 | 8/63 | 7/82 | 8/86 |
| Upper respiratory tract infectionInfections and infestations | 8/64 | 2/58 | 3/63 | 8/82 | 6/86 |
| CellulitisInfections and infestations | 0/64 | 0/58 | 3/63 | 0/82 | 5/86 |
| VomitingGastrointestinal disorders | 1/64 | 0/58 | 3/63 | 1/82 | 5/86 |
| Abdominal discomfortGastrointestinal disorders | 0/64 | 3/58 | 2/63 | 3/82 | 2/86 |
| DyspepsiaGastrointestinal disorders | 1/64 | 3/58 | 0/63 | 3/82 | 1/86 |
Intent to Treat (ITT) includes all participants who were randomized as specified in the protocol and received at least one dose of Investigational product (IP)
| Age, Continuous(years) | Placebo | Apremilast 30 mg | Apremilast 40 mg | Total |
|---|---|---|---|---|
| Mean | 37.7 ± 14.71 | 39.2 ± 15.80 | 38.3 ± 14.74 | 38.4 ± 15.00 |
| Sex: Female, Male(Participants) | Placebo | Apremilast 30 mg | Apremilast 40 mg | Total |
|---|---|---|---|---|
| Female | 39 | 27 | 32 | 98 |
| Male | 25 | 31 | 31 | 87 |
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
Data sharing details ↗ · www.amgen.com
The record gives a start of Jun 2014, a primary completion of Oct 2015 and a completion of Feb 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2016, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Apremilast